Ibogaine, a naturally occurring psychoactive alkaloid, is used within a global medical subculture to treat substance-related disorders, particularly opioid withdrawal. As of February 2006, an estimated 3,414 individuals had taken ibogaine—a fourfold increase from five years earlier—with 68% doing so for a substance-related disorder and 53% specifically for opioid withdrawal, the most common reason. The subculture lacks clinical and pharmaceutical standards, posing risks. Ethnographic analysis identified four types of ibogaine scenes: medical model, lay provider/treatment guide, activist/self-help, and religious/spiritual. The focus on opioid withdrawal distinguishes ibogaine from other psychedelics and aligns with experimental evidence of a significant pharmacologically mediated effect.
Between 1990 and 2008, nineteen individuals died within 1.5 to 76 hours after taking ibogaine, a plant alkaloid used for opioid detoxification. The deaths did not show a characteristic pattern of nerve damage. In 12 of the 14 cases with sufficient autopsy data, advanced preexisting medical conditions—mainly heart disease—or the presence of other abused drugs explained or contributed to the death. Additional risk factors included seizures from alcohol or benzodiazepine withdrawal and use of unregulated traditional forms of ibogaine.